Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Gains from Sales and Divestitures (2022 - 2023)

Ensysce Biosciences (ENSC) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $61001.0 as the latest value for Q4 2023.

  • On a quarterly basis, Gains from Sales and Divestitures rose 45.7% to $61001.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $61001.0, a 45.7% increase, with the full-year FY2023 number at $61001.0, up 45.7% from a year prior.
  • Gains from Sales and Divestitures was $61001.0 for Q4 2023 at Ensysce Biosciences, up from $938.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $61001.0 in Q4 2023 to a low of $312.0 in Q1 2023.